ÂÜÀòÂÒÂ×

Daniel Galbraith has extensive work experience in the life science industry. Daniel currently holds the position of Chief Technology Officer for Large Molecules and Advanced Therapies at Solvias since 2023. Prior to this, they worked at Merck Life Science as the Head of New Services and Technology Management from 2020 to 2023. From 2019 to 2020, they served as the Head of Product Characterization and New Services at Merck Group. Before that, they were the Director of Strategy and Product Characterization at BioReliance from 2017 to 2019. Mr. Galbraith also held the role of Chief Scientific Officer at Sartorius Stedim BioOutsource from 2007 to 2017, where they later became the Head of Operations in 2009. Daniel was the Head of BioSafety at Covance Laboratories from 2004 to 2007 and the Associate Director of Virology at MedImmune Vaccines from 2003 to 2004. Prior to that, they served as the Scientific Director at BioReliance from 1996 to 2003. Daniel also held the position of Head of Regulatory Affairs and Virology at Q-One Biotech during the same period. Mr. Galbraith began their career as a Postdoctoral Research Fellow at The University of Glasgow from 1992 to 1996.

Daniel Galbraith has a strong educational background in the field of science. Daniel obtained a Doctor of Philosophy (Ph.D.) degree in Immunology from the University of Abertay, where they studied from 1989 to 1992. Prior to that, they completed a Master of Science (MSc) degree in Forensic Science from the University of Strathclyde, from 1988 to 1989. Daniel also holds a Bachelor of Science (BSc Hons) degree in Microbiology, which they earned from the University of Glasgow from 1984 to 1988.

Additionally, Daniel has pursued some additional certifications to enhance their skills and knowledge. Daniel completed a certification on Unconscious Bias from LinkedIn in May 2021, and another certification on Leading Your Team Through Change, also from LinkedIn, in January 2021.